公开(公告)号：US11407763B2

公开(公告)日：2022-08-09

申请号：US16641604

申请日：2018-08-24

Applicant: GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY ,  KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY ,  KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION ,  CURACLE CO., LTD.

Inventor： Jin Hee Ahn ,  Hail Kim ,  Jaemyoung Suh ,  In-Kyu Lee ,  Kwang-eun Kim ,  Kun-Young Park ,  Eun Jung Bae ,  Ko Eun Shong ,  Suvarna Haus-habhau Pagire ,  Ajin Lim ,  Jae-Han Jeon ,  Haushabhau Shivaji Pagire ,  Haiying Zhang ,  Myung-Hwa Kim ,  Jung-In Pyo

IPC: C07D495/04 ,  C07D487/04 ,  C07D403/12 ,  C07D403/14 ,  C07D271/06 ,  C07D231/12 ,  C07D401/14 ,  C07D401/12 ,  C07D239/47 ,  C07D405/12 ,  C07D403/08 ,  A61P35/00 ,  A61P1/00 ,  C07D405/14

Abstract: The present invention relates to a novel tryptophan hydroxylase inhibitor and a pharmaceutical composition including same, wherein the novel tryptophan hydroxylase inhibitor has an excellent inhibitory effect on TPH1, and thus can be usefully used for the prevention or treatment of disorders, such as metabolic disorders, cancer, digestive or cardiovascular system disorders, related to TPH1 activity. In particular, the novel tryptophan hydroxylase inhibitor has an excellent treatment effect on inflammatory bowel disorders, and thus can be usefully used for the treatment of inflammatory bowel disorder.

公开(公告)号：US20210155634A1

公开(公告)日：2021-05-27

申请号：US16641604

申请日：2018-08-24

Applicant: GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY ,  KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY ,  KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION ,  CURACLE CO., LTD.

Inventor： Jin Hee Ahn ,  Hail Kim ,  Jaemyoung Suh ,  In-Kyu Lee ,  Kwang-eun Kim ,  Kun-Young Park ,  Eun Jung Bae ,  Ko Eun Shong ,  Suvarna Haus-habhau Pagire ,  Ajin Lim ,  Jae-Han Jeon ,  Haushabhau Shivaji Pagire ,  Haiying Zhang ,  Myung-Hwa Kim ,  Jung-In Pyo

IPC: C07D495/04 ,  C07D487/04 ,  C07D403/12 ,  C07D403/14 ,  C07D271/06 ,  C07D231/12 ,  C07D401/14 ,  C07D401/12 ,  C07D239/47 ,  C07D405/12 ,  C07D405/14 ,  C07D403/08 ,  A61P35/00 ,  A61P1/00

Abstract: The present invention relates to a novel tryptophan hydroxylase inhibitor and a pharmaceutical composition including same, wherein the novel tryptophan hydroxylase inhibitor has an excellent inhibitory effect on TPH1, and thus can be usefully used for the prevention or treatment of disorders, such as metabolic disorders, cancer, digestive or cardiovascular system disorders, related to TPH1 activity. In particular, the novel tryptophan hydroxylase inhibitor has an excellent treatment effect on inflammatory bowel disorders, and thus can be usefully used for the treatment of inflammatory bowel disorder.

公开(公告)号：US09988605B2

公开(公告)日：2018-06-05

申请号：US14453799

申请日：2014-08-07

Applicant: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Yong-mahn Han ,  Young-jin Kim ,  Hail Kim

IPC: C12N5/071 ,  A61K35/39 ,  G01N33/50 ,  C07K14/62 ,  A61K35/545

CPC classification number: C12N5/0677 ,  A61K35/39 ,  A61K35/545 ,  C07K14/62 ,  C12N2500/12 ,  C12N2500/38 ,  C12N2501/01 ,  C12N2501/115 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2501/335 ,  C12N2501/385 ,  C12N2501/41 ,  C12N2501/415 ,  C12N2501/727 ,  C12N2506/02 ,  C12N2506/45 ,  G01N33/507 ,  G01N2500/10

Abstract: The present invention prepared insulin-producing endocrine cells by inducing the differentiation of human embryonic stem cells or human induced pluripotent stem cells into definitive endoderm (DE), pancreatic endoderm (PE), endocrine progenitors (EP), and endocrine cells (EC) stepwise in that order. Particularly, the present invention established the conditions for the formation of an insulin producing endocrine aggregate (EA) from the endocrine cells. Especially in this invention, it was confirmed that the endocrine aggregate has the cell proliferation potential at a significant level and has the increased insulin productivity as well as the activity of inhibiting cell necrosis and apoptosis. Therefore, the method for preparing the endocrine aggregate of insulin-producing beta cells from human pluripotent stem cells can be effectively used for the examination of the medicinal effect of the conventional antidiabetic agents and of the novel antidiabetic drugs.